Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder.

ABSTRACT:

Purpose of review

This review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD).

Recent findings

Several new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women. New drugs under development are testosterone combined with sildenafil or buspiron, bremelanotide, BP101, and nasal testosterone (TBS-2).

Summary

Although pharmacological enhancement of sexual responsiveness may be potentially helpful in the treatment of FSIAD, the observed

SUBMITTER: Both S 

PROVIDER: S-EPMC5711968 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature